NEW YORK, Jan. 30-Cutbacks in service offerings and a new focus on drug development meant that CuraGen reported lower revenues and increased for the fourth quarter of 2002, the company said in an earnings report today.
...and receive Daily News bulletins.
Already have an account?Login Now.
The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.
Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.
Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.
In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.